Human Oncology and Pathogenesis Program Timothy A. Chan James A. Fagin William L. Gerald Marc Ladanyi Ross L. Levine Ingo Mellinghoff William Pao Charles L. Sawyers David B. Solit Members of the Laboratory Publications Career Opportunities Research > Memorial Hospital Research > Human Oncology and Pathogenesis Program > David B. Solit Publications 1. Solit D, Zheng F, Drobnjak M, Munster P, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus D, Scher H and Rosen N, 17-allyl-aminogeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts, Clin Cancer Res, 8:986-993, 2002. 2. Basso A, Solit D, Chiosis G, Giri B, Tsichlis P, Rosen N, Akt Forms an Intracellular Complex with Hsp90 and cdc37 and is Destabilized by Inhibitors of Hsp90 Function, J. Bio Chem, 277(42):39858-39866, 2003. 3. Yamamoto K, Garbaccio R, Stachel S, Solit D, Chiosis G, Rosen N, Danishefsky S, Cycloproparadicicol: A Fully Synthetic, Fully Active Point Mutant of Radicicol: Stereochemistry - Activity Relationships in the Radicicol Series, Agnew. Chem. Int. Ed.,42:1280-1284, 2003. 4. Solit D, Basso A, Olshen A, Scher H, Rosen N, Inhibition of Hsp90 Function Downregulates Akt Kinase and Sensitizes Tumors to Taxol, Cancer Res, 63:2139-2144, 2003. 5. Smith-Jones PM, Solit D, Akhurst T, Afroze F, Rosen N, Larson S, In Vivo Biodistribution and Non Invasive Quantification of HER2 Expressing Tumors in Nude Mice using 68Ga labeled Herceptin F(ab')2 Fragments, Nature Bio, 22(6), 701-6, 2004. 6. Yang Z, Geng X, Solit D, Pratilas C, Rosen N, Danishefsky S, New Efficient Synthesis of Resorcinylic Macrolides via Ynolides: Establishment of Cycloproparadicicol as Synthetically Feasible Preclinical Anticancer Agent Based on Hsp90 as the Target., J Am Chem Soc. 126(25):7881-7889, 2004. 7. Vilenchik M*, Solit D*, Basso A, Huezo H, Lucas B, Huazhong H, Rosen N, Spaminato C, Modrich P, and Chiosis G. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem. Biol., 11:787-797, 2004. 8. Solit D, She Y, Lobo J, Kris M, Scher H, Rosen N, Sirotnak F. Pulsatile administration of the EGF receptor inhibitor gefitinib ('Iressa', ZD1839) is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel ('Taxol'), Clin Cancer Res, 11:1983-89, 2005. 9. She Q, Solit D, Ye Q, O'Reilly K, Rosen N, Inhibition of both EGFR/MAP kinase signaling and PI3/AKT kinase signaling is required to activate the BAD protein and induce apoptosis in PTEN-deficient tumor cells, Cancer Cell,, 8:287-297, 2005. 10. Solit D, Garraway L, Pratilas C, Sawai A, Getz G, Basso A, Ye Q, Lobo J, She Y, Osman I, Golub T, Sebolt-Leopold J, Sellers W, Rosen N, BRAF mutation predicts sensitivity to MEK inhibition, Nature,439(7074):358-62, 2006, Epub 2005 Nov 6. 11. Grbovic O, Basso A, Sawai A, Ye Q, Friedlander P, Osman I, Solit D, Rosen N, V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors, Proc Natl Acad Sci USA, 103:57-62, 2006. 12. O'Reilly K, Rojo F, She Q, Solit D, Mills G, Smith D, Lane H, Hofmann F, Hicklin D, Ludwig D, Baselga J, Rosen N, mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt, Cancer Res, 66(3):1500-8, 2006. 13. Smith-Jones P, Solit D, Afroze F, Rosen N, Larson S, Early Tumor Response to Hsp90 Therapy using HER2-PET, J Nuc Med, 47(5):793-796, 2006. 14. Yang S, Qu S, Perez-Tores M, Rosen N, Solit D, Arteaga C, Association with HSP90 inhibits Cbl-mediated downregulation of mutant EGF receptors, Cancer Res, 66(14):6990-7, 2006.

Memorial Sloan-Kettering Cancer Center | Sloan-Kettering Institute Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan-Kettering Cancer Center

Site Map | Index	Legal Disclaimer | Privacy Practices | Public Notices
©2008 Memorial Sloan-Kettering Cancer Center. 212-639-2000 1275 York Avenue New York, NY 10065.	PublicAffairs@mskcc.org